A Phase I trial of WP1732 for treatment of pancreatic cancer
Phase of Trial: Phase I
Latest Information Update: 14 May 2019
Price : $35 *
At a glance
- Drugs WP 1732 (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions
- Sponsors Moleculin Biotech
- 14 May 2019 According to a Moleculin Biotech media release, an Investigational New Drug (IND) application is expected to submit in Q4-2019.
- 21 Feb 2019 According to a Moleculin Biotech media release, company will dose the first patient in 2020.
- 01 Dec 2018 New trial record